Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: Jongmans who wrote (56)	5/31/2000 10:20:00 PM
From: tommysdad	Respond to of 598

Thanks for that. Here's a nugget I didn't glean from the Tularik release: "JT will determine the research priorities for Tularik Pharmaceutical" Hmm . . . . . . Now, let me get this straight: TLRK already has collaborations in place with JT targetting nuclear orphans, and another targetting diabetes/obesity. What, exactly, is this new "metabolic disease" subsidiary going to do, that's not already covered by the current alliances? Methinks there is more to this than meets the eye.